Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 3(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06792994Recruiting

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Role: collaborator

NCT07107529Phase 2Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Role: collaborator

NCT02541383Phase 3Completed

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Role: collaborator

NCT02688140Phase 3Completed

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Role: collaborator

NCT00766779Phase 3Terminated

HCT Versus CT in Elderly AML

Role: collaborator

NCT00140582Phase 3Completed

Primary Rituximab and Maintenance

Role: collaborator

NCT00209209Phase 3Unknown

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Role: collaborator

All 7 trials loaded